Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40
What this study shows
Structures reveal how RHEB allosterically activates and PRAS40 inhibits mTORC1.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Cryo-EM structure) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Cryo-EM structure |
| Journal | Nature |
| Year | 2017 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1038/nature25023 · PMID 29236692 · Free full text (PMC5750076) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Structural (cryo-EM) |
| Target | mTORC1 / RHEB / PRAS40 |
| Model | Cryo-EM structure |
| Effect | Structures reveal how RHEB allosterically activates mTORC1 and how PRAS40 inhibits it |
In the Atlas
Related topics
Links in the pathway map
- Supports PRAS40 inhibits mTORC1
- Supports Rheb activates mTORC1
More studies on this topic
- The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1 (2007)
- PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase (2007)
- Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 (2007)
Was this page useful?
Thank you. Your answer was counted anonymously.